Prosecution Insights
Last updated: November 04, 2026
Application No. 18/866,933

SYSTEM AND METHOD FOR MONITORING UROLOGY DISEASES AND SYMPTOMS

Non-Final OA §102
Filed
Nov 18, 2024
Priority
May 18, 2022 — provisional 63/343,113 +2 more
Examiner
HOEKSTRA, JEFFREY GERBEN
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Caretech Human Inc.
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
2y 0m
Est. Remaining
96%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
304 granted / 540 resolved
-13.7% vs TC avg
Strong +40% interview lift
Without
With
+39.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 0m
Avg Prosecution
67 currently pending
Career history
624
Total Applications
across all art units

Statute-Specific Performance

§101
9.3%
-30.7% vs TC avg
§103
27.5%
-12.5% vs TC avg
§102
37.9%
-2.1% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 540 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group 1, drawn to the system for monitoring urological symptoms, in the reply filed on 8/28/26 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Applicant’s election without traverse of Group 1 in the reply filed on 8/28/26 is acknowledged. Claims 71-79 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 8/28/26. Initially with respect to the election of species requirement, the Examiner agrees with and appreciates Applicant’s attention to indicating the typographical error in the Election of Species requirement mailed 7/1/26, wherein the second listed species should have indeed been listed as and read “Species B” instead of a duplicate and erroneously redundant “Species A”. Applicant's election with traverse of Species A, embodiment drawn to Figures 3 and 5A-5C, in the reply filed on 8/28/26 is acknowledged. The traversal is on the ground(s) that Fig 6 of Species B depicts the apparatus illustrated in Figs 5A and 5B in isolation while not mounted on a toilet bowl. This is not found persuasive because while those relationships may be true they do not preclude the embodiment of Species B and Fig 6 from being independent and/or distinct such that a search and/or examination burden exists. The Examiner respectfully notes the Species are the embodiments indicated via Figures but also include the detailed description(s) thereof in the instant disclosure, wherein Species B, while also being used in a toilet bowl although not shown in the figure, includes significant details regarding the sensor ID not present in and mutually exclusive with Species A. The requirement is still deemed proper and is therefore made FINAL. Claims 69-70 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected species, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 8/28/26. Applicant is reminded that upon the cancelation of claims to a non-elected invention, the inventorship must be corrected in compliance with 37 CFR 1.48(a) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. A request to correct inventorship under 37 CFR 1.48(a) must be accompanied by an application data sheet in accordance with 37 CFR 1.76 that identifies each inventor by his or her legal name and by the processing fee required under 37 CFR 1.17(i). Information Disclosure Statement The accompanying information disclosure statement (IDS) submission(s) is/are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Specification The lengthy specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant’s cooperation is requested in correcting any errors of which applicant may become aware in the specification. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 60-68 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wang et al. (WO 2021/174474 A1, hereinafter Wang) (reference herein is made with respect to accompanying English translation). For claim 60, Wang discloses a system for monitoring urological symptoms, the system comprising inter alia: a sampling reservoir (12) (Fig 1) (Pgs 7-14) comprising an opening (opening of 12) and having a liquid (toilet bowl water) held therein (Fig 1) (Pgs 7-14), the sampling reservoir configured to receive a biomaterial sample from a user through the opening (Fig 1) (Pgs 7-14); a first sensor (11,33,51) (Fig 1) disposed proximate to the sampling reservoir (Fig 1) (Pgs 7-14), the first sensor configured to: measure a parameter of the liquid (Fig 1) (Pgs 7-14); and generate a signal in response to the measurement (Fig 1) (Pgs 7-14); and a computing node (24), the computing node configured to receive the signal from the first sensor (Fig 1) (Pgs 7-14), and determine therefrom a parameter of the biomaterial sample (Fig 1) (Pgs 7-14). For claim 61, Wang discloses the system of claim 60, wherein the parameter of the liquid is an amplitude of at least one wave formed in the liquid (Fig 1) (Pgs 7-14). For claim 62, Wang discloses the system of claim 61, wherein the at least one wave is formed in the liquid in response to deposition of the biomaterial sample into the liquid (Fig 1) (Pgs 7-14), and wherein the amplitude of the at least one wave is correlated with a urination flow pattern (Fig 1) (Pgs 7-14). For claim 63, Wang discloses the system of claim 60, wherein the sampling reservoir is a toilet bowl (12) (Fig 1) (Pgs 7-14). For claim 64, Wang discloses the system of claim 60, wherein the biomaterial sample is urine voided from the user (Fig 1) (Pgs 7-14). For claim 65, Wang discloses the system of claim 60, wherein the computing node is further configured to generate an electronic diary entry in response to the signal from the first sensor, the electronic diary entry having a datum corresponding to the signal (Pgs 7-14). For claim 66, Wang discloses the system of claim 60, wherein: the computing node is configured to extract one or more features from the signal (Pgs 7-14), wherein the one or more features comprises a void frequency and provide the one or more features to a machine learning (ML) model (Pgs 7-14). For claim 67, Wang discloses the system of claim 66, wherein the parameter includes one or more of a flow rate, a voided volume, a flow pattern, and a urination time (Pgs 7-14). For claim 68, Wang discloses the system of claim 60, wherein the computing node is configured to generate a probability score in response to the signal from the sensor, wherein the probability score corresponds to a probability the user has a disease (Pgs 7-14). Conclusion The cited prior art made of record on the accompanying PTO-892 and not relied upon is considered pertinent to applicant's disclosure, relating to means for monitoring/tracking urine voiding parameters via toilet bowl sensing. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey G. Hoekstra whose telephone number is (571)272-7232. The examiner can normally be reached Monday through Thursday from 5am-3pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles A. Marmor II can be reached at (571)272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Jeffrey G. Hoekstra Primary Examiner Art Unit 3791 /JEFFREY G. HOEKSTRA/ Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Nov 18, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778514
SEQUENTIALLY-REDUCED ARTIFICIAL INTELLIGENCE METHODOLOGY FOR INSTANTANEOUS DETERMINATION OF WAVEFORM INTRINSIC FREQUENCIES
3y 11m to grant Granted Nov 03, 2026
Patent 12751645
METHODS AND DEVICES FOR MOTION MONITORING
3y 6m to grant Granted Oct 06, 2026
Patent 12751653
FLUID CONTROL DEVICES AND METHODS OF USING THE SAME
2y 4m to grant Granted Oct 06, 2026
Patent 12745947
EVALUATION OF PAIN DISORDERS VIA EXPERT SYSTEM
5y 0m to grant Granted Sep 29, 2026
Patent 12745991
IMPROVED BIOPSY ARRANGEMENT
3y 6m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
96%
With Interview (+39.7%)
4y 0m (~2y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 540 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month